Inebilizumab shows benefit in patients with gMG
29 Apr 2025
byElaine Soliven
Treatment with inebilizumab significantly improved generalized myasthenia gravis (gMG) symptoms, as shown by a greater reduction in MG-Activities of Daily Living (MG-ADL) scores, among patients who were acetylcholine receptor antibody-positive (AChR-Ab+) or muscle-specific kinase antibody-positive (MuSK-Ab+), according to the phase III MINT* trial presented at AAN 2025.